ISPOR President Reflects on COVID-19 Challenges and Lasting Achievements

President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and Director and Partner at Boston Consulting Group Dr. Jens Grueger shares his thoughts on his ISPOR presidency during the COVID-19 pandemic. Moving to virtual meetings led to widespread technical difficulties, despite substantial benefits such as reaching a wider audience. The pandemic also forced ISPOR to consider its financial standing and how to prepare for a post-COVID landscape.

Dr. Grueger remarks, “My vision as ISPOR President included 3 priorities: (1) advancing the science of health economics and outcomes research (HEOR) to address innovative treatment options; (2) broadening the reach of ISPOR to expand capacity for health technology assessment (HTA) and HEOR in low- and middle-income countries (LMIC); and (3) building the leadership pipeline within ISPOR.” Read more here.

(Source: Jens Grueger, Value & Outcomes Spotlight, ISPOR, 5/2021)